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INTRODUCTION
Atherosclerosis is a diffuse, systemic disease of the
arterial network, the local manifestations of which are
associated with clinical problems such as myocardial
infarction, stroke, etc. Vulnerable lesions (high risk
plaques) are characterized by a large necrotic core, a thin
fibrous layer (fibroatheroma), and an inflammatory
infiltrate (monocytes/macrophages, T lymphocytes, and
mastocytes, etc). Although the rupture of a fibrous plaque
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is the main cause of intraluminal thrombosis in acute
coronary syndromes and is responsible for 75% of all
deaths following acute myocardial infarction, thrombosis
has also been observed in eroded plaques and in those
with calcified nodules.1,2 In high risk patients, plaque
vulnerability is a multifocal phenomenon that involves
different lesions around the coronary tree. In clinical
practice, the signs of vulnerable plaques are difficult to
discern. Current efforts directed towards identifying
patients at risk are therefore based on three types of
markers: a) images (eg, magnetic resonance, optical
coherence tomography, molecular imaging, etc), for
characterizing the composition of atheroma plaques and
identifying those that are vulnerable; b) functional markers
of vascular homeostasis (eg, arterial thickening and the
endothelial-dependent vasodilatory response); and 
c) circulating markers (based on the measurement of
Defects in the synthesis and breakdown of the
extracellular matrix (ECM) are now seen as key
processes in the development of atherosclerosis and its
thrombotic complications. Correlations have been
observed between circulating levels of ECM biomarkers
and the clinical manifestations of and risk factors for
atherosclerosis. Several matrix metalloproteinases
(MMPs), endopeptidases that can degrade the ECM,
such as MMP-9 and MMP-10, play important roles in the
pathophysiology of atherothrombosis and contribute to
the expansion of abdominal aortic aneurysms. Moreover,
they may also be useful biomarkers of atherosclerotic risk
and serve as predictors of coronary and cerebrovascular
disease recurrence. Although at present the effect of
tissue inhibitors of MMPs (TIMPs) on cardiovascular
disease prognosis is still uncertain, the ECM could be a
promising therapeutic target in atherothrombotic disease,
and several MMP inhibitors are currently undergoing
clinical trials.
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Metaloproteasas, remodelado vascular 
y síndromes aterotrombóticos
Las alteraciones en la síntesis y/o la degradación de la
matriz extracelular (MEC) emergen como procesos clave
en el desarrollo de la aterosclerosis y sus complicaciones
trombóticas. Se ha observado una asociación entre los
biomarcadores circulantes de la MEC y las manifestacio-
nes clínicas y los factores de riesgo ateroscleróticos. Di-
versas metaloproteasas (MMP), endopeptidasas que 
degradan la MEC, como MMP-9 y 10, además de desem-
peñar un papel relevante en la fisiopatología del proceso
aterotrombótico y contribuir a la expansión de los aneu-
rismas arteriales, pueden ser de utilidad como biomarca-
dores de riesgo aterosclerótico y predictores de recurren-
cia de enfermedad coronaria y cerebrovascular. Aunque
actualmente el papel de los inhibidores de MMP (TIMP)
en el pronóstico cardiovascular es más incierto, la MEC
puede representar una diana terapéutica atractiva en la
aterotrombosis, y diversos inhibidores de las MMP se en-
cuentran en fase de investigación clínica.
Palabras clave: Aterosclerosis. Matriz extracelular. Re-
modelado vascular. Biomarcadores.
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markers of inflammation, oxidative stress, and thrombosis
in the blood).3-6 The use of biomarkers of extracellular
matrix (ECM) remodeling has been less studied, even
though the ECM provides the structural and functional
platform for the blood vessels; changes in its synthesis
and/or breakdown must therefore play a key role in the
development of atherosclerotic lesions, vascular
remodeling, and plaque rupture.7,8 This has led to the
proposal that certain matrix metalloproteinases (MMP),
such as pregnancy-associated plasma protein A (PAPP-A),9
may serve as potential biomarkers of atherosclerotic
progression. A loss of equilibrium between the molecules
and factors that induce the degradation of the ECM and
those that favor its synthesis and accumulation could be
of prime importance in the development of clinical
atherothrombotic syndromes.
PHYSIOLOGY OF THE EXTRACELLULAR
MATRIX
The arterial wall is dominated by collagen type I and
II, macrophages, and smooth muscle cells; these cell
types govern the remodeling of the ECM. Fibronectin,
laminin, elastin, and proteoglycans are also involved in
ECM synthesis. The balance between ECM synthesis
and breakdown is regulated by the equilibrium between
the proteases that favor degradation (MMP) and their
tissue inhibitors (TIMP) (Figure 1). The MMP are a
family of zinc-dependent endopeptidases produced by
monocytes, endothelial cells, and smooth muscle cells,
whose function it is to break down numerous components
of the ECM as well as other proteins not associated with
it. They are synthesized and secreted as inactive
proenzymes with a propeptide domain rich in cysteine
able to fold and interact with the Zn++ of the catalytic
domain – thus impeding any enzyme activity. Activation
requires the removal of the propeptide domain. Based
on their structure, substrate specificity, and membrane
binding (Table), these enzymes are classified as
collagenases (MMP-1, 8, and 13), stromelysins (MMP-
3, 10, and 11), gelatinases (MMP-2 and 9), membrane-
type MMP (MT-MMP), and others (matrilysin,
metalloelastase, etc).10 Their activity is regulated
transcriptionally, post-translationally, and via interactions
with specific inhibitors. A number of growth factors,
cytokines, thrombin, and hormones increase the
transcription of these enzymes, while heparin,
transforming growth factor beta (TGFβ) and corticoids
inhibit it.11,12 The extracellular activation of latent
zymogens (pro-MMP molecules) provides a second
control point. The main physiological activator of the
MMP is plasmin, which converts inactive forms into
active molecules by the proteolysis of the propeptide link
and the exposure of the catalytic domain.13 Other enzymes,
such as thrombin, factor Xa, and the MMP themselves
also possess MMP-activating activity. Finally, the activity
of the MMP is regulated by TIMP, of which four are
known (TIMP-1, 2, 3, and 4). Inhibition is achieved via
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Figure 1. Synthesis and breakdown of the
extracellular matrix in atherosclerosis: balance
between metalloproteases (MMP) and their
inhibitors (TIMP).
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the irreversible binding of these molecules to the active
enzyme. Thus, in summary, the proteolytic balance
depends on the relative concentration of activators and
inhibitors13 (Figure 1). 
THE EXTRACELLULAR MATRIX 
AND ATHEROTHROMBOSIS
The equilibrium between MMP and TIMP is critical
in the maintenance of the integrity of the cardiovascular
system.13-16 This has led to the proposal that any alteration
towards the breakdown of the ECM contributes to the
progression of atherosclerosis and plaque instability.17
Certainly, the participation of the MMP in different
mechanisms fundamental to atherothrombotic progression
has been reported (Figure 2):
– MMP favor monocyte infiltration of the vascular
wall. An increase in the expression of certain MMP, such
as MMP-12, leads to macrophage infiltration, the rupture
of the internal elastic lamina, and the acceleration of the
atherosclerotic process.18
– The induction and activation of the MMP, particularly
MMP-14 (MT1-MMP), favors the invasion of plaques
by vascular smooth muscle cells and fibroblasts. The
migration and proliferation of these cell types is important
in the development of intimal hyperplasia.19,20
– The activity of MMP-2 and 9, among others, is
indispensable for the neovascularization of atherosclerotic
plaques. This process, induced by proangiogenic and
inflammatory stimuli, appears to be necessary for their
growth, and is associated with the vulnerability of
advanced lesions.21,22
– The role of MMP in the formation and resolution of
thrombi remains somewhat unclear (Figure 3). An
abnormal reduction in the activity of ADAMTS-13 favors
the appearance of thrombotic microangiopathies,23
and there is evidence of molecular interactions between
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TABLE. Characteristics and Specificity of the Main Metalloproteases*
MMP (Type) Name ECM Substrate
Collagenases
MMP-1 Collagenase-1 Collagen I, II, III, VII, VIII, and X, gelatin, proteoglycans, tenascin, entactin
MMP-8 Collagenase-2 Collagen I, II, III, V, VIII, and X, gelatin, aggrecan
MMP-13 Collagenase 3 Collagen I, II, III, IV, IX, X, and XIV, gelatin, tenascin, fibronectin, aggrecan, osteonectin
Gelatinases
MMP-2 Gelatinase A Collagen I, IV, V, VII, X, XI, and XIV, gelatin, elastin, fibronectin, laminin, aggrecan, versican, osteonectin,
proteoglycans
MMP-9 Gelatinase B Collagen IV, V, VII, X, XIV, gelatin, elastin, aggrecan, versican, proteoglycans, osteonectin
Stromelysins
MMP-3 Stromelysin-1 Collagen III, IV, V, and IX, gelatin, aggrecan, versican, proteoglycan, tenascin, fibronectin, laminin, 
osteonectin
MMP-10 Stromelysin-2 Collagen III, IV, V, gelatin, casein, aggrecan, elastin, proteoglycans
MMP-11 Stromelysin-3 Casein, laminin, fibronectin, gelatin, collagen IV, transferrin
Membrane type
MMP-14 MT1-MMP Collagen I, II, and III, casein, elastin, fibronectin, vitronectin, tenascin, proteoglycans, laminin, entactin
MMP-15 MT2-MMP Tenascin, fibronectin, laminin
MMP-16 MT3-MMP Collagen III, gelatin, casein, fibronectin
MMP-17 MT4-MMP ND
MMP-24 MT5-MMP ND
MMP-25 MT6-MMP ND
Others
MMP-7 Matrilysin Collagen IV and X, gelatin, aggrecan, proteoglycans, fibronectin, laminin, entactin, tenascin, casein, 
transferrin, integrin b4, osteonectin, elastin
MMP-12 Metalloelastase Collagen IV, gelatin, elastin, casein, laminin, proteoglycans, fibronectin, vitronectin, entactin
MMP-20 Enamelysin amelogenin
MMP-23A MMP-21 ND
MMP-23B MMP-22 ND
MMP-26 Matrilysin 2 Collagen IV, fibrinogen, fibronectin, casein
MMP-27 ND ND
MMP-28 Epilysin Casein
*ECM indicates extracellular matrix; MMP, metalloproteinases; ND, not determined. 
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MMP-3 and enzymes, substrates, and inhibitors of the
fibrinolytic system. This suggests the MMP to have some
role in the latter.24 They might therefore be involved in
different types of thrombotic disease. Finally, thrombi
themselves may be a source of proteolytic activity that
might be important in the atherothrombotic process.25
The physiopathological importance of changes in
ECM metabolism in the development of atherothrombotic
syndromes is supported by numerous pieces of evidence.
It is interesting to note that intravascular thrombosis and
acute myocardial infarction are rare consequences of
restenosis (one of the limitations of percutaneous
revascularization). Restenotic plaques appear as a
consequence of the rapid proliferation of vascular smooth
muscle cells and the accumulation of ECM at the lesion
site. These plaques, however, rarely rupture or express
MMP-9 (gelatinase B).26 In contrast, the progress of an
atherosclerotic plaque from a fatty streak to an advanced,
unstable element is slow, and is associated with an
increase in its cellular and ECM contents as well as in
proteolytic activity. This latter activity is mainly
associated with the macrophages and vascular smooth
muscle cells at the plaque shoulders and around the
necrotic core, and is accompanied by the expression and
concentration of (mostly) MMP-1 (collagenase), and
MMP-9.27,28 An increase in the gelatinase MMP-9 has
also been observed in the coronary plaques of patients
with unstable angina compared to those with stable
angina,29,30 and has been related to post-infarction
ventricular remodeling.31,32 Increased concentrations of
MMP-9 have also been reported in human brain tissue
following ischemic and hemorrhagic ictus, and the
induction of MMP-9 has been reported in the cerebral
vasculature following fibrinolysis. This indicates that
this enzyme may contribute to ischemic cerebral lesions
and perihematomal edema as well as to cerebral
hemorrhages and neurovascular lesions following
fibrinolysis.33,34 These local alterations can be detected
at the systemic level; patients with angiographic proof
of coronary heart disease show an alteration in the balance
of fibrinolysis/proteolysis in their peripheral blood.35 In
addition, it has been reported that the urine MMP-9
concentration increases, while that of TIMP-1 is reduced,
after an acute myocardial infarction.36
The expression and activity of MMP-9 in an
atherosclerotic plaque, which is mainly associated with
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macrophages, may be the consequence of an increase in
the production of the NADPH-dependent superoxide
anion since it coincides with the expression of NADPH
oxidase and the production of free radicals.37 However,
the gelatinases and collagenases are not the only MMP
associated with atherosclerosis; our group has recently
shown an increase in MMP-10 (stromelysin 2) in advanced
carotid plaques obtained by endarterectomy.38 MMP-10
has also been associated with aortic aneurysms, which
are characterized by destructive remodeling of the vascular
ECM and rupture of the wall.39 Finally, the TIMP-1
concentrations have been reported to increase in calcified
areas of human atherosclerotic plaques,40 further indicating
the inhibition of MMP activity may be related to greater
plaque instability.
METALLOPROTEASES AND
ATHEROSCLEROTIC RISK FACTORS
The majority of the classic risk factors for
atherosclerosis have been related to changes in the
concentrations of different ECM biomarkers and the
overall Framingham score.41,42 The mechanisms behind
this, however, are unclear. It may be that the risk factors
modulate the vascular structure and stability of plaques,
which in turn influence concentrations of MMP and
TIMP, or via modifications in collagen production. Neither
can it be ruled out that modified biomarker values are an
epiphenomenon or an adaptive response to the process
of atherosclerosis.
Age and Sex
Advanced age and male sex have been related to
elevated concentrations of TIMP-1.41 Hormone therapy
has been reported to reduce MMP-9 concentrations in
post-menopausal women.43
Dyslipemia
In the clinical setting, the Framingham Heart Study
reported MMP-9 to be detectable only in 20% of subjects,
in whom it was associated with high levels of low-density
lipoprotein cholesterol (LDL-C).42 In contrast, TIMP-1
was detected in all subjects and increased with the total
cholesterol/high-density lipoprotein cholesterol (HDL-C)
ratio.41 In subjects with familial hypercholesterolemia, an
increase has been reported in concentrations of MMP-3
and 9, and TIMP-1, particularly in those at greater
cardiovascular risk–in whom the serum concentrations of
MMP-3 and TIMP-1 have been associated with carotid
atherosclerotic lesions.44 In addition, the abnormally high
levels of MMP-9 in patients with familial
hypercholesterolemia and coronary heart disease can be
reduced through treatment with statins, although no
correlation between the reduction of the MMP concentration
and lower cholesterol concentrations is reported.45
Under experimental conditions it has been shown that,
following angioplasty, the vascular expression of MMP-1
increases in a porcine hypercholesterolemic model,
perhaps as a consequence of oxidative stress.46 In in vitro
experiments, oxidized LDL has been shown to increase
the production of MMP-1, 3, and 9, while that of TIMP-1
is reduced. In contrast, HDL reduces the production of
several MMP types.47,48 In monocytes/macrophages it
has been reported that oxidized LDL acts synergistically
with proinflammatory factors to induce the expression
of MMP-1 and MMP-9, while HDL prevents the induction
of MMP-1 via these same agents.49
Diabetes, Obesity, and Metabolic Syndrome
MMP-9 and TIMP-1 are increased in patients with
diabetes and metabolic syndrome.50,51 In experimental
studies it has been observed that increased glucose levels
induce the expression of MMP-1 and 2 by endothelial
cells, and of MMP-9 by macrophages, but have no effect
on TIMP-1.52 In a clinical study involving patients with
diabetes, the control of blood sugar and atherosclerotic
risk factors reduced TIMP-1 without modifying MMP-
9 or TIMP-2.53
The concentration of TIMP-1, but not of MMP-9, has
been related to body mass index.41 Finally, in a study
involving obese women, a reduction in MMP-1 was
noticed one year after performing stomach reduction
surgery.54
High Blood Pressure
An increase in circulating MMP-9 – but also of TIMP-1
– has been reported in patients with high blood pressure and
general thickening of the artery walls.55 High blood
pressure is associated with an increase in collagen
synthesis and a reduction in its breakdown.56
Tobacco and Alcohol
Smokers show increased concentrations of MMP-9
and TIMP-1, the extent of which is partly related to the
duration of tobacco exposure.57 No association has been
reported between the abusive intake of alcohol and
circulating TIMP-1 and MMP-2 concentrations,58 although
an increase in MMP-9 and 2 expression has been reported,
especially in the alveolar macrophages. The latter is
probably related to lung remodeling in the context of
acute respiratory distress syndrome.59 An inverse
association has been reported between moderate alcohol
consumption and circulating TIMP-1 concentrations.41
Inflammation
Different inflammatory stimuli, such as TNFα and
interleukin 1, as well as other factors, regulate the
expression of MMP.60 In experimental studies it has been
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shown that C-reactive protein, an inflammatory biomarker
of atherosclerotic risk, induces the expression of MMP-1
by macrophages, and of MMP-10 by endothelial cells,
without affecting TIMP-1 concetrations.38,61 It has also
been reported that circulating MMP-9 concentrations in
patients with coronary heart disease, which are higher
than those in healthy subjects, are directly associated
with the concentrations of inflammation markers such
as plasma C-reactive protein, interleukin 6, and fibrinogen.
However, no differences in nor association with the
MMP-2 levels have been reported.62 Similarly, in other
clinical studies involving asymptomatic subjects,
C-reactive protein have been associated with those
of MMP-9 and 10, but not with those of MMP-2 or
MMP-3.38 Recently, our group has shown that 
C-reactive protein induces the expression of MMP-1 and
MMP-10 by human endothelial cells, and that
asymptomatic subjects with a proinflammatory profile
show elevated concentrations of MMP-10.38 Doxycycline,
which reduces the concentration of C-reactive protein
also reduces the activity of MMP-9.63 It has been proposed
that the infection of macrophages or smooth muscle cells
with Chlamydia pneumoniae can induce the production
of MMP since a strong relationship has been seen between
the presence of this bacterium and the immunodetection
of MMP-9 in atherosclerotic plaques. However, no causal
relationship has been established.64
PROGNOSTIC VALUE OF EXTRACELLULAR
MATRIX BIOMARKERS
Quantification of the turnover of the ECM in
cardiovascular tissues faces methodological difficulties.
The different procedures available for evaluating
fibrosis/degeneration in tissues (eg, endomyocardial
biopsy, intravascular ultrasonography, etc) are, apart from
being invasive, of limited use. Further, circulating ECM
biomarkers are not specific for vascular tissue, and since
MMP binds ECM components a local increase does not
always correlate with a systemic increase. Currently, it
is unsure which of the 40 possible ECM biomarkers has
the best prognostic value. Therefore, when establishing
criteria for the selection of biomarkers of interest and
clinical applicability, certain factors should taken into
account: a) it should be demonstrated that markers reflects
the remodeling of the ECM, b) there should be evidence
that high concentrations are found in patients with stable
disease, c) the biomarker should be stable in plasma or
serum, and d) the method should be standardized and
show little variability. As well as showing good
reproducibility, biomarkers should be helpful in arriving
at a diagnosis, at a prognosis, and in the therapeutic
monitoring of atherosclerosis.3,4
Several studies have reported an association between
MMP and TIMP that predicts an adverse prognosis in a
wide range of cardiovascular diseases.65-68 The most
promising circulating biomarkers of ECM breakdown
are MMP-9 (gelatinase B) and 10 (stromelysin 2). An
increase in MMP-9 predicts a narrowing of the arterial
lumen, restenosis after the positioning of a stent, and
cardiovascular death in patients with coronary heart
disease.69-72 It has also been related to the expansion and
rupture of aortic aneurysms73,74 and increases the risk of
hemorrhagic transformation in patients with ictus.75 These
biomarkers may also offer prognostic information in the
primary prevention setting. MMP-9 predicts ischemic
heart disease, and/or high blood pressure in patients with
no prior cardiovascular disease,76 and our group has
recently shown that MMP-10 provides a marker of
subclinical atherosclerosis; a correlation was seen between
plasma MMP-10 levels and the thickness of the intima
media of the carotid artery in a large group of patients
with no history of cardiovascular disease.77
THE EXTRACELLULAR MATRIX 
AS A THERAPEUTIC TARGET 
IN ATHEROTHROMBOSIS
Modulation of pericellular proteolysis may be a good
target for therapeutic intervention in the context of
atherosclerosis.78 Perhaps the most representative example
of the effect of therapeutic agents on vascular remodeling
is provided by thrombolytic treatment. This stimulates
the expression of MMP via plasmin, and promotes the
degradation of collagen.79 Statins also reduce the
concentration of MMP-9 and other MMP,80,81 as do
angiotensin II type I receptor antagonists,82 while other
agents with cardiovascular action (such as carvedilol 
and the thiazolidinediones) reduce concentration of 
MMP-1.83,84 Certain antibiotics, such as doxycycline and
the tetracyclins, reduce the vascular and systemic
expression of several MMP,63 while antioxidants reduce
the expression of MMP-1.46
Several pharmaceutical companies are interested in
developing synthetic inhibitors of MMP, although none
are yet available for clinical use.85,86 Some experimental
studies show that the inhibition of MMP via the use of
TIMP may delay the progression of an atherosclerotic
plaque.71,87 In addition, the inhibition of MMP in the
advanced stages of atherosclerosis can protect against
the development of unstable plaques, the formation of
aneurysms and heart failure.88,89
CONCLUSIONS
Numerous studies have shown that the remodeling of
the ECM of artery walls can be monitored by determining
the circulating concentration of different MMP and TIMP.
These molecules can be considered biomarkers of
prognostic potential with respect to the recurrence of
ischemic heart disease, the development of heart failure,
and the formation of aneurysms in patients with clinical
atherosclerosis. They may also be used in asymptomatic
subjects with risk factors or in those with subclinical
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atherosclerosis. Prospective studies currently underway
should allow us to clarify the diagnostic and prognostic
potential of these biomarkers in vascular diseases, and
to assess their prospects as new therapeutic targets in
atherosclerosis.
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